Lichen Planus HQ (LPHQ) is committed to providing trustworthy, research-backed information and being transparent about our leadership and sources of support.
Medical Disclaimer
The information provided by Lichen Planus HQ, including information on our website, social media, educational materials, and events, is intended for general educational and informational purposes only. It is not intended to provide medical advice, diagnosis, or treatment and should not replace care from a qualified healthcare professional. We do not endorse any specific treatments for lichen planus.
Always consult your healthcare provider with questions about your health, diagnosis, or treatment. Do not delay or discontinue medical care based on information provided by Lichen Planus HQ.
Conflicts of Interest
LPHQ is committed to transparency regarding relevant financial and professional relationships of our leadership team. These relationships do not influence LPHQ’s educational content or activities.
Erin Foster, MD, PhD
- LEO Pharma: Site Principal Investigator for a clinical trial of delgocitinib for genital lichen sclerosus
- Aclaris Therapeutics: Scientific advisor
- Arcutis Biotherapeutics: Previous collaboration related to a genital psoriasis consensus and publication
All other members of the LPHQ leadership team report no relevant financial relationships with pharmaceutical or biotechnology companies.
Funding Sources
Lichen Planus HQ is committed to transparency regarding the financial support we receive.
Current funding:
- Metropolitan Medical Foundation of Oregon — $1,800
LPHQ currently receives no funding from pharmaceutical companies or other pharmaceutical industry sources.
Funding does not determine or influence the educational information, recommendations, or perspectives presented by Lichen Planus HQ.
Sharing Our Content
Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of Lichen Planus HQ (LPHQ).
Last updated: August 2026